Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ2 | O43526 | 7/20 | 0.45 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.45 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.45 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.45 |
| ▸ | CSF1R | P07333 | 3/20 | 0.42 |
| ▸ | PPARD | Q03181 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | VNN1 | O95497 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30794782 | 0.88 | KCNQ3 (0.48) | KCNQ2KCNQ3KCNQ4KCNQ5CSF1R | |
| SCHEMBL2069786 | 0.88 | KCNQ3 (0.48) | KCNQ2KCNQ3KCNQ4KCNQ5CSF1R | |
| SCHEMBL3106787 | 0.83 | RAB9A (0.44) | KCNQ2KCNQ3KCNQ4KCNQ5CSF1R | |
| SCHEMBL30795031 | 0.77 | TRPV1 (0.42) | KCNQ2KCNQ3KCNQ4KCNQ5L3MBTL1 | |
| SCHEMBL3109635 | 0.77 | TRPV1 (0.42) | KCNQ2KCNQ3KCNQ4KCNQ5L3MBTL1 | |
| SCHEMBL30795327 | 0.73 | KCNQ3 (0.48) | KCNQ2KCNQ3KCNQ4KCNQ5CSF1R | |
| SCHEMBL2071107 | 0.73 | KCNQ3 (0.48) | KCNQ2KCNQ3KCNQ4KCNQ5CSF1R | |
| SCHEMBL23177713 | 0.72 | L3MBTL1 (0.56) | KCNQ2L3MBTL1 | |
| SCHEMBL22288452 | 0.72 | KCNQ3 (0.59) | KCNQ2KCNQ3KCNQ4KCNQ5 | |
| SCHEMBL25291060 | 0.71 | HPGD (0.47) | KCNQ2KCNQ3KCNQ4KCNQ5L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256145-A1 | USE OF KCNQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | H. LUNDBECK A/S (DK) | 2010-10-07 | — | — | US | claimed |
| CN-101790374-A | Use of kncq potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted | LUNDBECK & CO AS H | 2010-07-28 | — | — | CN | claimed |
| EP-2185149-A1 | USE OF KNCQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | H. Lundbeck A/S (DK) | 2010-05-19 | — | — | EP | claimed |
| US-20100063044-A1 | SUBSTITUTED ANILINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2010-03-11 | — | — | US | claimed |
| WO-2009015667-A1 | USE OF KNCQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | H. LUNDBECK A/S (DK) | 2009-02-05 | — | — | WO | claimed |
| CN-101056845-A | Substituted aniline derivatives | LUNDBECK & CO AS H (DK) | 2007-10-17 | — | — | CN | claimed |
| EP-1791809-A1 | SUBSTITUTED ANILINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2007-06-06 | — | — | EP | claimed |
| US-20060155121-A1 | Substituted aniline derivatives | H. LUNDBECK A/S (DK) | 2006-07-13 | — | — | US | claimed |
| WO-2006029623-A1 | SUBSTITUTED ANILINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2006-03-23 | — | — | WO | claimed |
| EP-4580679-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | Biohaven Therapeutics Ltd. (VG) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |
| CN-101378742-B | Use of KCNQ-openers for the preparation of a pharmaceutical composition for the treatment of schizophrenia | LUNDBECK & CO AS H | 2013-07-10 | — | — | CN | disclosed |
| EP-2554162-A1 | Use of KCNQ-Openers for Treating or Reducing the Symptoms of Schizophrenia | H. Lundbeck A/S (DK) | 2013-02-06 | — | — | EP | disclosed |
| EP-1983974-A1 | USE OF KCNQ-OPENERS FOR TREATING OR REDUCING THE SYMPTOMS OF SCHIZOPHRENIA | H. Lundbeck A/S (DK) | 2008-10-29 | — | — | EP | disclosed |
| CN-101056845-A | Substituted aniline derivatives | LUNDBECK & CO AS H (DK) | 2007-10-17 | — | — | CN | disclosed |
| WO-2007090409-A1 | USE OF KCNQ-OPENERS FOR THREATING OR REDUCING THE SYMPTOMS OF SCHIZOPHRENIA | H. LUNDBECK A/S (DK) | 2007-08-16 | — | — | WO | disclosed |
| EP-1791809-A1 | SUBSTITUTED ANILINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2007-06-06 | — | — | EP | disclosed |
| US-20060155121-A1 | Substituted aniline derivatives | H. LUNDBECK A/S (DK) | 2006-07-13 | — | — | US | disclosed |
| WO-2006029623-A1 | SUBSTITUTED ANILINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2006-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063044-A1 | SUBSTITUTED ANILINE DERIVATIVES | NDUFS3, NAT1, PRMT3 | KCNQ2 332/4885KCNQ3 304/4885KCNQ4 434/4885 |
| US-20060155121-A1 | Substituted aniline derivatives | UGT2B7, NAT1, CYP1A2 | KCNQ2 2118/4885KCNQ3 2451/4885KCNQ4 3102/4885 |
| US-20100256145-A1 | USE OF KCNQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | KCNQ2, KCNQ4, KCNQ1 | KCNQ2 1/4885KCNQ3 4/4885KCNQ4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.